Enovis (NYSE:ENOV) Stock: Insider Angela Lalor Buys 870 Shares

Enovis Corporation (NYSE:ENOV – Get Free Report) Director Angela Lalor bought 870 shares of the business’s stock in a transaction dated Wednesday, November 11th. The shares were bought at an average price of $28.86 per share, with a total value of $25,108.20. Following the purchase, the director owned 33,243 shares in the company, valued at $959,392.98. The trade was a 2.69% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Enovis Stock Performance

ENOV traded up $0.10 during trading on Friday, hitting $27.74. The stock had a trading volume of 1,205,392 shares, compared to its average volume of 1,879,055. The company has a 50 day moving average price of $20.52 and a 200-day moving average price of $23.22. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -3.01 and a beta of 1.31. Enovis Corporation has a one year low of $16.70 and a one year high of $31.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.08.

Enovis (NYSE:ENOV – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. The firm had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The business’s revenue was up 1.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.75 EPS. As a group, research analysts predict that Enovis Corporation will post 3.15 EPS for the current year.

Enovis News Roundup

Investors following ENOV have been watching these news items:

  • Positive Sentiment: Directors Angela S. Lalor and Sharon Wienbar bought a combined 3,531 shares in transactions on November 10 and 11, investing about $100,000. Insider buying can signal confidence, though the purchases are relatively small compared with the company’s overall market value. Lalor SEC filing Wienbar SEC filing
  • Neutral Sentiment: Enovis management will present at the Jefferies Global Healthcare Conference on November 17. The announcement may give investors an opportunity to hear updates, but it included no new guidance or business developments. Conference announcement

Institutional Investors Weigh In On Enovis

Large investors have recently bought and sold shares of the stock. IFP Advisors Inc raised its holdings in Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after buying an additional 1,174 shares during the last quarter. Allworth Financial LP acquired a new position in shares of Enovis during the second quarter valued at about $36,000. Integrated Wealth Concepts LLC acquired a new position in shares of Enovis during the second quarter valued at about $39,000. Public Employees Retirement System of Ohio bought a new stake in shares of Enovis during the second quarter worth about $48,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Enovis during the third quarter worth about $55,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on ENOV. BTIG Research upped their price objective on Enovis from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Citizens Jmp decreased their price target on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Citigroup reaffirmed a “market outperform” rating on shares of Enovis in a research note on Wednesday, September 2nd. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Finally, Canaccord Genuity Group reduced their price objective on shares of Enovis from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Friday, November 6th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and an average target price of $38.62.

Get Our Latest Report on Enovis

About Enovis

(Get Free Report)

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

Featured Articles

Insider Buying and Selling by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.